Carien Creutzberg is Professor of Radiation Oncology at Leiden University Medical Center. She has conducted clinical research to improve the treatment of gynecological cancers, reduce side effects, improve quality of life and understand the origin and individual properties of these cancers for over 30 years.

As the initiator and chief investigator of the four successive national and international PORTEC-trials on treatment of endometrial cancer, her work has impacted treatment guidelines worldwide. She initiated the TransPORTEC Consortium, highlighting the value of international collaboration in clinical trials. This consortium’s joint translational research contributing to the PORTEC-3 trial resulted in new knowledge on the molecular characteristics of endometrial cancer, and their prognostic and predictive role in adjuvant treatment.

Through her nationwide and international collaboration and membership of the Gynecologic Cancer Intergroup, she was co-founder and board member of the multidisciplinary Dutch Gynecological Oncology Group. She was member of the Dutch Cancer Society Advisory Board, chair of the GCIG Endometrial Cancer Committee and Endometrial Consensus Conference, Council member of the International Gynecologic Cancer Society and of the European Society of Gynecological Oncology and member of the European Society for Medical Oncology Gyne Faculty.

Dr. Creutzberg’s academic achievements, leadership, and collaborative spirit make her an inspirational figure in gynecologic oncology. The presentation of the IGCS Lifetime Achievement Award is a testament to her remarkable professional journey, which demonstrates the importance of multidisciplinary and international collaboration to improve the understanding of gynecologic cancers and advancement of care worldwide.